Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks .

What is Syndax Pharmaceuticals' stock price target for 2024?

10 Wall Street analysts have issued 12-month price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $28.00 to $43.00. On average, they anticipate the company's share price to reach $35.09 in the next year. This suggests a possible upside of 115.3% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts .

How have SNDX shares performed in 2023?

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 36.0% and is now trading at $16.30. View the best growth stocks for 2023 here .

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SNDX earnings forecast .

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) , ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI) . Simplify Health Care ETF (PINK) .

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK) , Exelixis (EXEL) , Verastem (VSTM) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Idera Pharmaceuticals (IDRA) , TherapeuticsMD (TXMD) and Micron Technology (MU) .

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avidity Partners Management LP (4.05%), Jennison Associates LLC (3.38%), Adage Capital Partners GP L.L.C. (1.44%), Group One Trading L.P. (0.00%), Northern Trust Corp (0.91%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alexander Nolte , Briggs Morrison , Dennis Podlesak , Fabrice Egros , Keith A Goldan, Keith Katkin, Michael A Metzger , Michael L Meyers , Peter Ordentlich , Pierre Legault and William Meury. View institutional ownership trends .

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Syndax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNDX)

$16.54

+0.24 (+1.47%)

(As of 09:46 AM ET)

Compare

Today's Range: $16.47
▼
$16.77
50-Day Range: $11.39
▼
$16.30
52-Week Range: $11.22
▼
$29.86

Volume: 69,770 shs
Average Volume: 1.08 million shs
Market Capitalization: $1.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.09

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 115.3% Upside
$35.09 Price Target
Short Interest: Bearish
15.25% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 0.63
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.97) to ($3.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

528th out of 949 stocks

Pharmaceutical Preparations Industry

258th out of 445 stocks

4.5

Analyst's Opinion

Consensus Rating
Syndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.09, Syndax Pharmaceuticals has a forecasted upside of 115.3% from its current price of $16.30.
Amount of Analyst Coverage
Syndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
15.25% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Syndax Pharmaceuticals has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Syndax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syndax Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Syndax Pharmaceuticals is -1.12.

2.0

News and Social Media Coverage

News Sentiment
Syndax Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
6 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Syndax Pharmaceuticals is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($2.97) to ($3.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syndax Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syndax Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syndax Pharmaceuticals has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNDX Stock News Headlines

November 24, 2023 | americanbankingnews.com

Comparing Syndax Pharmaceuticals (NASDAQ:SNDX) & RVL Pharmaceuticals (NASDAQ:RVLP)

November 24, 2023 | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Buy" by Analysts

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 21, 2023 | finance.yahoo.com

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

November 7, 2023 | finance.yahoo.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Could Be 49% Below Their Intrinsic Value Estimate

November 7, 2023 | finance.yahoo.com

Syndax Announces Participation at Stifel Healthcare Conference

November 6, 2023 | markets.businessinsider.com

Promising Clinical Trials and Strong Financial Health Drive Buy Rating for Syndax Pharmaceuticals

November 6, 2023 | markets.businessinsider.com

Promising Pipeline Developments and Upcoming Approvals Bolster Buy Rating for Syndax Pharmaceuticals

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cencora (COR), Syndax Pharmaceuticals (SNDX) and AMN Healthcare Services (AMN)

November 3, 2023 | markets.businessinsider.com

Maintained Buy Rating on Syndax Pharmaceuticals: Promising Clinical Profiles and Consistent Cash Flow

November 3, 2023 | finance.yahoo.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Syndax Pharmaceuticals Inc (SNDX) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

November 2, 2023 | finance.yahoo.com

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

October 28, 2023 | finance.yahoo.com

Bank of America Says Contrarian Buy Signal Could Push Stocks Higher; Here Are 2 Names the Banking Giant Likes Right Now

October 27, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Quest Diagnostics (DGX) and Syndax Pharmaceuticals (SNDX)

October 27, 2023 | msn.com

Stifel Maintains Syndax Pharmaceuticals (SNDX) Buy Recommendation

October 26, 2023 | finance.yahoo.com

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

October 25, 2023 | msn.com

B of A Securities Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation

October 24, 2023 | finance.yahoo.com

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

October 17, 2023 | markets.businessinsider.com

Analyst Ratings for Syndax Pharmaceuticals

October 13, 2023 | seekingalpha.com

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023

October 12, 2023 | msn.com

Goldman Sachs Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation

October 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Teladoc (TDOC)

October 3, 2023 | markets.businessinsider.com

Syndax Pharmaceuticals Receives Buy Rating Following Promising AUGMENT-101 Study Results for Revumenib in Acute Leukemia Treatment

October 2, 2023 | proactiveinvestors.com

Syndax Pharmaceuticals shares fall despite positive leukemia trial

See More Headlines

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNDX
CUSIP: N/A
CIK: 1395937
Web: www.syndax.com
Phone: (781) 419-1400
Fax: 781-419-1420
Employees: 107
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.09
High Stock Price Target: $43.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +115.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-149,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.37%
Return on Assets: -39.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.73
Quick Ratio: 9.73

Sales & Book Value

Annual Sales: $139.71 million
Price / Sales: 8.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.16 per share
Price / Book: 3.16

Miscellaneous

Outstanding Shares: 69,640,000
Free Float: 66,368,000
Market Cap: $1.14 billion
Optionable: Optionable
Beta: 1.04

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Michael A. Metzger M.B.A. (Age 52)
CEO & Director
Comp: $1.05M
Mr. Keith Alan Goldan CPA (Age 52)
CFO, Treasurer & Chief Accounting Officer
Comp: $649.07k
Mr. Luke J. Albrecht (Age 43)
Senior VP, General Counsel & Secretary
Comp: $605.82k
Dr. Catherine Madigan M.D. (Age 51)
Chief Medical Officer
Comp: $764.41k
Mr. Steve M. Sabus (Age 57)
Chief Commercial Officer
Comp: $523.44k
Dr. Peter Ordentlich B.Sc. (Age 54)
Ph.D., Co-Founder & Chief Scientific Officer
Dr. Richard A. Heyman Ph.D. (Age 66)
Co-Founder
Dr. Ronald M. Evans Ph.D. (Age 74)
Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D.
Co-Founder
Sharon Klahre
Vice President of Investor Relations & Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.
What is Syndax Pharmaceuticals' stock price target for 2024?: 10 Wall Street analysts have issued 12-month price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $28.00 to $43.00. On average, they anticipate the company's share price to reach $35.09 in the next year. This suggests a possible upside of 115.3% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.
How have SNDX shares performed in 2023?: Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 36.0% and is now trading at $16.30.
View the best growth stocks for 2023 here.
When is Syndax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SNDX earnings forecast.
How were Syndax Pharmaceuticals' earnings last quarter?: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07.
What ETFs hold Syndax Pharmaceuticals' stock?: ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Syndax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).
When did Syndax Pharmaceuticals IPO?: (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Who are Syndax Pharmaceuticals' major shareholders?: Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avidity Partners Management LP (4.05%), Jennison Associates LLC (3.38%), Adage Capital Partners GP L.L.C. (1.44%), Group One Trading L.P. (0.00%), Northern Trust Corp (0.91%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends.
How do I buy shares of Syndax Pharmaceuticals?: Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Syndax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNDX)

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

SNDX Stock Price History

SNDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SNDX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™